-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple system atrophy (MSA) is a rare adult-onset progressive neurodegenerative disorder characterized by a variable combination of diminished autoregulation, Parkinsonism, cerebellar ataxia, and pyramidal signs
.
MSA progresses rapidly and there is no effective treatment; median survival is approximately 6 to 10 years
.
Shorter duration of symptoms at baseline and unresponsiveness to levodopa have been reported to predict rapid disease progression
Disease progression was faster in patients with autonomic dysfunction as initial symptoms and in women with MSA
.
In addition to the non-motor symptoms of autonomic dysfunction commonly seen in MSA, cognitive impairment is not uncommon
In addition to worsening motor function, marked cognitive decline was observed in MSA
.
There is an urgent need for biomarkers that can predict MSA progression
Neurofilament light chain (NFL) has received increasing attention not only in cerebrospinal fluid (CSF) but also in serum as a candidate biomarker for axonal damage in neurodegenerative diseases
.
It has been shown that the plasma NFL of MSA patients is higher than that of Parkinson's disease patients and healthy controls (HCs)
.
However, studies on the relationship between NFL levels and the severity and progression of MSA are lacking
Hereby, Lingyu Zhang et al.
, from West China Hospital, examined plasma NFL levels in MSA patients to investigate whether plasma NFL levels were associated with MSA severity, and to elucidate the relationship between plasma NFL and MSA progression
.
Patients with MSA were part of a prospective cohort study assessed at baseline and 1 year later
.
Plasma NFL was quantified using the ultrasensitive Simoa technology
A total of 91 MSA patients and 60 healthy controls (HCs) participated in the study
.
Levels of NFL increased from baseline to 1-year follow-up (P = 0.
The significance of the study lies in the findings; plasma NFL is a reliable biomarker for measuring MSA disease severity and monitoring MSA progression , but not with cognitive progression
.
Original source:
Zhang L, Cao B, Hou Y, et al.
Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy.
leave a message here
